Gemphire Therapeutics Inc. (GEMP) Upgraded at Zacks Investment Research
Gemphire Therapeutics Inc. (NASDAQ:GEMP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The firm presently has a $10.00 price objective on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 5.04% from the stock’s previous close.
According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
A number of other research analysts have also weighed in on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $31.00 price target on shares of Gemphire Therapeutics in a research note on Monday. Roth Capital began coverage on shares of Gemphire Therapeutics in a research note on Thursday. They issued a “buy” rating and a $30.00 price target on the stock. HC Wainwright began coverage on shares of Gemphire Therapeutics in a research note on Thursday, August 31st. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Jefferies Group LLC decreased their price target on shares of Gemphire Therapeutics from $32.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, August 8th. Six research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $23.33.
Shares of Gemphire Therapeutics (GEMP) traded up 2.15% during trading on Monday, hitting $9.52. The stock had a trading volume of 48,886 shares. The firm’s market cap is $101.16 million. The firm has a 50 day moving average price of $9.65 and a 200 day moving average price of $9.65. Gemphire Therapeutics has a 12-month low of $7.20 and a 12-month high of $21.59.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.99) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.28). On average, equities analysts expect that Gemphire Therapeutics will post ($3.18) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Gemphire Therapeutics Inc. (GEMP) Upgraded at Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/gemphire-therapeutics-inc-gemp-upgraded-at-zacks-investment-research.html.
A number of institutional investors have recently modified their holdings of the stock. Northpointe Capital LLC lifted its stake in Gemphire Therapeutics by 91.8% in the 3rd quarter. Northpointe Capital LLC now owns 520,292 shares of the company’s stock valued at $4,943,000 after buying an additional 249,077 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in Gemphire Therapeutics by 1.7% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 153,064 shares of the company’s stock worth $1,959,000 after purchasing an additional 2,500 shares in the last quarter. GM Advisory Group Inc. purchased a new position in Gemphire Therapeutics in the 2nd quarter worth approximately $457,000. Vanguard Group Inc. lifted its stake in Gemphire Therapeutics by 137.6% in the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after purchasing an additional 17,892 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Gemphire Therapeutics in the 1st quarter worth approximately $184,000. 29.70% of the stock is currently owned by hedge funds and other institutional investors.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.